Table 1.
Immunological and virological characteristics of the HIV-1-infected infants
| Control | LTA | RP | ||||
|---|---|---|---|---|---|---|
| No. HIV-1 children | 17 | 7 | 14 | |||
| Age (years), (mean ± s.e.m. (range)) | 12·5 ± 0·6 | (7·2; 16·0) | 10·9 ± 1·4 | (7·5; 16·9) | 11·6 ± 0·8 | (7·7; 17·4) |
| Immunological characteristics, (mean ± s.e.m. (range)) | ||||||
| % CD4+ | 44.0 ± 1·5 | (32·4; 51·1) | 34·5 ± 1·7 | (26·7; 38·6)** | 9·1 ± 1·8 | (1·2; 21·7)**‡ |
| CD4+ T/mm3 | 1072.0 ± 138 | (557; 2097) | 935.0 ± 80·6 | (657; 1298) | 133.0 ± 17·8 | (9; 225)**‡ |
| % CD8+ | 24·1 ± 1·3 | (19·5; 34·7) | 36·9 ± 2·5 | (28·7; 45·4)** | 61·2 ± 4·2 | (37·6; 86·5)**‡ |
| CD8+ T/mm3 | 582.0 ± 86 | (262; 1198) | 991.0 ± 102 | (760; 1370)* | 1129.0 ± 215 | (356; 2791)** |
| Virological characteristics | ||||||
| Log10 VL (copies/ml), (mean ± s.e.m. (range)) | – | 2·48 ± 0·08 | (2·30; 2·88) | 3·83 ± 0·35 | (2·30; 5·40) | |
| Undetectable VL (<400 copies/ml) | 6 (85·7%) | 4 (28·6%)† | ||||
| Anti-retroviral therapies | ||||||
| NT | – | 2 | – | |||
| MT | – | – | – | |||
| CT | – | 5 | – | |||
| HAART | – | – | 14 | |||
VL: viral load. HIV-1: Human Immunodeficiency virus type-1. NT: Not treated; MT: Monotherapy; CT: Combination therapy; HAART: highly active antiretroviral therapy.
*
Differences with control group (P < 0·05)
**
Differences with control group (P < 0·01).
†
Differences significant with LTA group (P < 0·05)
‡
Differences significant with LTA group (P < 0·01).